Cantabio Pharmaceuticals (CTBO) 10-K 14 Jul 16 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2016	Sep. 30, 2015
Document and Entity Information
Entity Registrant Name	Cantabio Pharmaceuticals Inc.
Document Type	10-K
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Entity Central Index Key	1,550,518
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding	26,805,270
Entity Public Float		$ 0
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	ctbo

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Current Assets
Cash	$ 52,110	$ 209
Total Current Assets	52,110	209
TOTAL ASSETS	52,110	209
Current Liabilities
Accounts payable and accrued expenses	225,498	214
Accrued technology access fee	173,414	214,745
Due to officers	6,420	3,706
Notes payable related party	16,562
Total Current Liabilities	421,894	218,665
TOTAL LIABILITIES	421,894	218,665
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock value	26,805	14,824
Stock subscriptions	500,000
Additional paid-in capital	99,324
Accumulated deficit	(995,913)	(233,280)
Total Stockholders' Equity (Deficit)	(369,784)	(218,456)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 52,110	$ 209

Balance Sheets (parenthetical)

Balance Sheets (parenthetical) - $ / shares	Mar. 31, 2016	Mar. 31, 2015
Balance Sheet
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	26,129,594	14,824,324
Common stock, shares outstanding	26,129,594	14,824,324

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement
Revenues
Operating Costs and Expenses
Research and development expense	149,159	14,022
General and administrative expenses	691,778	15,659
Total operating costs and expenses	840,937	29,681
Income (loss) from operations	(840,937)	(29,681)
Other Income and (Expenses)
Grant income		34,744
Other income		1,953
Gain (loss) on extinguishment of debt	107,884
Gain (loss) on foreign exchange	(18,275)	71,288
Total other income and (expenses)	8	107,985
Net income (loss)	$ (751,328)	$ 78,303
Basic and diluted earnings (loss) per share	$ (0.04)	$ 0.01
Weighted average common shares outstanding - basic and diluted	18,216,544	14,824,324

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Shares	Shares to be Issued	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
Beginning Balance, shares at Mar. 31, 2014	14,824,324
Beginning Balance, amount at Mar. 31, 2014	$ 14,824			$ (311,583)	$ (296,759)
Net income (loss) for the period				78,303	78,303
Ending Balance, shares at Mar. 31, 2015	14,824,324
Ending Balance, amount at Mar. 31, 2015	$ 14,824			(233,280)	(218,456)
Cancellation of stock, shares	(444,730)
Cancellation of stock, value	$ (445)			445
Stock issued to acquire shell company, shares	11,750,000
Stock issued to acquire shell company, value	$ 11,750			(11,750)
Stock subscriptions		$ 600,000			600,000
Stock issued, shares	675,676
Stock issued, value	$ 676	(100,000)	$ 99,324
Net income (loss) for the period				(751,328)	(751,328)
Ending Balance, shares at Mar. 31, 2016	26,805,270
Ending Balance, amount at Mar. 31, 2016	$ 26,805	$ 500,000	$ 99,324	$ (995,913)	$ (369,784)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ (751,328)	$ 78,303
Adjustments to reconcile net loss to net cash used by operating activities:
Gain (loss) on extinguishment of debt	107,884
Changes in operating assets and liabilities:
(Increase) decrease in accounts payable and accruals	225,285	(72,001)
(Increase) decrease in accrued technology fee	66,553
(Increase) decrease in due to officers	2,714	(6,121)
Net cash provided by (used in) operating activities	(564,660)	179
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party notes payable	33,755
Repayments of related party notes payable	17,194
Proceeds from stock subscriptions	600,000
Net cash provided by financing activities	616,561
Net increase (decrease) in cash	51,901	179
Cash, beginning of period	209	30
Cash, end of period	52,110	$ 209
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES
Issuance of common stock in satisfaction of share subscription agreement	$ 100,000

Organization and Description of

Organization and Description of The Business	12 Months Ended
	Mar. 31, 2016
Notes
Organization and Description of The Business	NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE BUSINESS Cantabio Pharmaceuticals Inc. (the “Company” or “Cantabio”) is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from research and development activities for Parkinson’s disease (PD) and Alzheimer’s disease (AD). The Company’s strategy involves integration of therapeutic focus, the targeting of family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which synergizes to identify and develop small molecule pharmacological chaperones for clinical trials. In addition, the Company’s research efforts concentrate on the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins with display loss of function during disease conditions. Merger Agreement On December 17, 2015, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Gardedam Therapeutics, Inc. (“Gardedam”) and Cantabio Acquisition Inc., the wholly-owned subsidiary of the Company (“Merger Sub”), pursuant to which Gardedam would become its wholly-owned subsidiary. The Merger Agreement provided that, upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into Gardedam (the “Merger”), with Gardedam continuing as the surviving corporation and as the wholly-owned subsidiary of the Company. The Merger was completed on the date of the Merger Agreement. Prior to the Merger Agreement date, the CEO of Gardedam returned 30,000 shares of Gardedam stock to treasury and these were cancelled, equivalent to approximately 445,000 shares of Company stock. On the date of the Merger Agreement, each Gardedam share was exchanged for 14.82 shares of Company stock. The Company accounted for the transaction as a reverse merger, with the operations of Gardedam being the accounting acquirer and the historical financial statements of Gardedam presented. The statement of stockholders’ equity was retroactively adjusted to reflect the shares outstanding of the legal acquirer, which resulted in a retroactive adjustment to the par value of common stock outstanding for Gardedam and an adjustment to accumulated deficit for the difference.

Liquidity and Going Concern Dis

Liquidity and Going Concern Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Liquidity and Going Concern Disclosure	NOTE 2 - LIQUIDITY AND GOING CONCERN The accompanying financial statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) which contemplate continuation of the Company as a going concern. As of March 31, 2016, the Company had a working capital deficit of $369,784 and losses from operations. This and other factors raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2016
Notes
Summary of Significant Accounting Policies	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation These financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions are eliminated upon consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Income Taxes The Company complies with the FASB ASC No. 740 - Income Taxes which requires an asset and liability approach to financial accounting and reporting for income taxes. For any uncertain tax positions, the Company recognizes the impact of a tax position only if it is more likely than not of being sustained upon examination, based on the technical merits of the position. Given the lack of certainty over the Company’s ability to make profits in future the Company has not recorded any deferred tax asset in the accounts. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are carried at cost, which approximates fair value. The Company places its cash and cash equivalents on deposit with a financial institution in the United States. The Federal Deposit Insurance Corporation (FDIC) covers $250,000 for substantially all depository accounts in the United States. The Company from time to time may have amounts on deposit in excess of the insured limits. Fair Value of Financial Instruments The Company's financial instruments consist of cash, accounts payable, and a loan payable to a related party. The carrying amounts of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements. Share Subscriptions Under the terms of a subscription agreement the Company has received funds pursuant to an issuance of stock. The stock is only issuable to the investors once the full subscription proceeds are received, which will not occur until fiscal year 2017. While the shares are un-issued it is the policy of the company to account for the received capital as Share Subscriptions. Earnings per Share The Company calculates earnings per share in accordance with Financial Accounting Standards Board (FASB) ASC No. 260 - EPS, which requires that basic net income per common share be computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. The Company has no share option scheme and as a result no dilutive elements were considered for the purposes of calculating earnings per share. Recent Accounting Pronouncements Fiscal 2017 Accounting Pronouncement Adoptions Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU No. 2014-15”) that will require management to evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the financial statements are issued on both an interim and annual basis. Management will be required to provide certain footnote disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. ASU No. 2014-15 becomes effective for us in the first quarter of fiscal 2017. The Company is currently evaluating the impact of ASU 2014-15 on its financial statements. Fiscal 2019 Accounting Pronouncement Adoptions Leases In February 2016, the FASB issued ASU 2016-02, Leases

Material Agreements Disclosure

Material Agreements Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Material Agreements Disclosure	NOTE 4 - Material Agreements Graffinity Collaboration Agreement On December 23, 2009, the Company entered into a collaboration agreement with Graffinity, GmbH. Graffinity GmbH was subsequently acquired by NovAliX Deutschland GmbH, and on November 12, 2015 the Company renegotiated the terms of the agreement setting aside all unperformed terms and modifying the payable as laid out below. NovAliX Collaboration Agreement - DJ-1 On November 12, 2015, the Company finalized the amendment to its collaboration agreement with NovAliX Deutschland GmbH, which modifies the remaining amount owed of approximately $215,000 as of March 31, 2015 to approximately $120,000 on November 12, 2015. The amended agreement set aside, along with any unperformed actions under the prior contract, and stated that the new collaboration agreement would constitute the entire agreement and understanding between NovAliX and the Company. NovAliX granted the company a worldwide, perpetual, non-exclusive right to sublicense to use certain compounds, synthesized compounds and other information provided by NovAlix to use against the DJ-1 protein. The Collaboration agreement resulted in a reduction in the Company’s accounts payable of approximately $107,884, which was recorded in other income (expense) and a payment of $32,000. The remaining $88,000 is due in fiscal 2017. NovAliX Collaboration Agreement - ABeta On March 23, 2016, the Company entered into a collaboration agreement with NovAliX Deutschland GmbH to use technology related to the protein ABeta. The terms of the agreement required an initial payment of approximately $80,000, payable within 4 years, which would accrue interest at 20% per annum from the date of signing until the balance is paid. A further payment of approximately $80,000 is payable upon commercialization of the technology.

Related Party Transactions Disc

Related Party Transactions Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Related Party Transactions Disclosure	NOTE 5 - RELATED PARTY TRANSACTIONS Gergely Toth During the year ended March 31, 2016 and 2015 the Company incurred approximately $2,700 and $3,700 of fees associated with work Gergely Toth did as CEO of the Company. The costs represent out of pocket expenditures that have not been reimbursed. The costs are included in general and administrative expense. Toth and Associates LTD On April 1, 2015, the Company entered into a consulting agreement with Toth and Associates, LTD for Dr. Toth to act as the Company’s CEO. The agreement calls for a standard monthly fee of approximately $12,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital. The Company incurred consulting fees and bonuses of approximately $200,000 for the twelve months ended March 31, 2016. As of March 31, 2016, Toth and Associates LTD was owed approximately $62,000, comprising $12,000 fees and $50,000 bonus, the directors having satisfied the valuation milestone detailed as (B) above. The $62,000 is included in Accounts payable. Capro LTD On April 1, 2015, the Company entered a consulting agreement with Capro, LTD for Dr. Thomas Sawyer to act as the Company’s COO. The agreement calls for a standard monthly fee of approximately $10,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital. The Company incurred consulting fees and bonuses of approximately $170,000 for the twelve months ended March 31, 2016. As of March 31, 2016, Capro LTD was owed approximately $60,000, comprising $10,000 fees and $50,000 bonus, the directors having satisfied the valuation milestone detailed as (B) above. The $60,000 is included in Accounts payable. Eden Professional LTD On April 1, 2015, the Company entered a consulting agreement with Eden Professional LTD for Mr. Simon Peace to act as the Companies CFO. The agreement calls for a standard monthly fee of approximately $6,000 plus any additional uncontracted hours at the same rate, and bonuses as follows (A) upon raising of capital on behalf of, or as part of the Company, an amount equal to 1.5% of the capital raised, (B) increasing the performance of the Company as measured by valuation in either an agreed valuation in the context of an investment or, in the case of a public company, market capitalization reaching $30.0 million, a fixed bonus of $50,000, payable wholly or in mutually agreed tranches over a 6 month period subsequent to the valuation event and (C) on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital. The Company incurred consulting fees and bonuses of approximately $130,000 for the twelve months ended March 31, 2016. In addition to the amount set out in Note 6 below, as of March 31, 2016, Eden Professional LTD was owed approximately $56,000, comprising $6,000 fees and $50,000 bonus, the directors having satisfied the valuation milestone detailed as (B) above. The $56,000 is included in Accounts payable. Prior to the merger of the Company and the shell company, both companies entered into related party transactions with Capro LTD, an entity that is wholly owned by our Chief Operating Officer. Interest-free loans were made from the Company to Capro totalling approximately $36,800. Capro LTD also made similar interest free loans to the shell company totalling $36,800 on the same dates and in the same amounts as it received from the Company. During this time Capro acted as agent of the shell company, paying the shell company’s expenses as necessary. By the date of the merger all funds were exhausted and there remained only Capro’s obligation of $36,800 to the Company, and the shell company’s obligation of $36,800 to Capro. At the time of the reverse merger, these loans were cancelled out, and as a result are no longer outstanding. The proceeds from the loans were utilized in connection with the reverse merger and were primarily associated with legal fees.

Notes Payable Related Parties D

Notes Payable Related Parties Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Notes Payable Related Parties Disclosure	NOTE 6 - NOTES PAYABLE RELATED PARTIES Officers of the Company loaned funds totaling $34,000 to the company to fund operating expenses. The loans were unsecured, non-interest bearing, and had no specific terms of repayment. As of March 31, 2016, the balance of the loans was approximately $16,562.

Capital Stock Disclosure

Capital Stock Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Capital Stock Disclosure	NOTE 7 - CAPITAL STOCK General Information The Company is authorized to issue 250,000,000 shares at a par value of $0.001. All common shares outstanding have equal voting rights. Stock Subscriptions During the year ended March 31, 2016, the Company received stock subscriptions totaling $500,000 from a syndicate of investors who signed a memorandum of understanding on April 12, 2015, and a subscription agreement on October 31, 2015. The terms of the agreement provide for $1.5 million of investment over 18 months from April 2015. The subscribed shares will be held in escrow until payment of the full amount of the investment. The Company expects to issue the subscribed portion of the shares to escrow during Q3 2016. The Company expects to close the financing in the first quarter of the 2017 calendar year. On August 18, 2015, the Company received a subscription totaling $100,000 from a private investor. Final Placement Under the terms of the stock subscription agreement signed on October 31, 2015, any shares subscribed for should be held in escrow until the full investment of $1.5 million is paid. As of March 31, 2016 the subscribed shares had not been issued to escrow. On February 26, 2016, 675,676 shares were issued in satisfaction of the earlier ($100,000) investment from the private investor.

Commitments and Contingencies D

Commitments and Contingencies Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Commitments and Contingencies Disclosure	NOTE 8 - COMMITMENTS Leases on Property On February 3, 2016, the Company entered into a lease on an office property in Sunnyvale, CA. The monthly lease payments total approximately $1,200, with a termination notice period of one month. On March 31, 2016, the Company entered into a lease on a Laboratory in Budapest, Hungary. The monthly lease payments total approximately $2,700, and the initial lease term is for 1 year with provisions allowing the contract to roll forward on the same terms thereafter. Neither party may terminate within one year, save for the lessor being allowed to terminate upon non-payment of rent, and thereafter there exists a termination notice period of 15 days.

Income Taxes Disclosure

Income Taxes Disclosure	12 Months Ended
	Mar. 31, 2016
Notes
Income Taxes Disclosure	NOTE 9 - INCOME TAXES The Company had no income tax expense due to operating losses incurred for the years ended March 31, 2016 and 2015. The difference between the statutory federal tax rate of 34% and the effective tax rate is summarized below: March 31, March 31, 2016 2015 Federal tax at statutory rate: 34.0% 34.0% State taxes (net of Federal benefit) 5.8% 5.8% Permanent difference -0.1% 0.0% Change in Valuation Allowance -39.7% -39.8% Provision for Income Taxes 0.0% 0.0% The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows: March 31, March 31, 2016 2015 Net Operating Loss Carryforwards 305,000 66,000 Accrued Bonus 60,000 -- Valuation Allowance (365,000) (66,000) Net Deferred Tax Assets -- -- At March 31, 2016, the Company had federal and state net operating loss tax carryforwards of approximately $764,000. These net operating loss carryforwards expire in various amounts starting in 2029. The Company has not filed tax returns since inception. The utilization of the federal and state net operating loss carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards. In addition, the maximum annual use of net operating loss and research credit carryforwards is limited in certain situations where changes occur in stock ownership. At March 31, 2016 and 2015, the Company has provided a full valuation allowance against its net deferred assets since realization of these benefits is not likely to be realized. The valuation allowance has increased by $299,000 as of March 31, 2016. As of March 31, 2016 and 2015, the Company had no unrecognized tax benefits. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2016
Notes
Subsequent Events	NOTE 10 - SUBSEQUENT EVENTS Receipt of further investment funds The Company received further investment funds under the October 2015 subscription agreement referred to in Note 7 totaling $0.425 million during May, June and July 2016. The Company agreed an addendum to the October 2015 subscription agreement for an additional $0.06 million of investment, on the same terms as in the subscription agreement, to fund investor relations activities. The Company signed a Trade Secret License Agreement with the Purdue Research Foundation to use and commercialize certain intellectual property relating to small molecule compounds that bind to the DJ-1 protein. The license fee is $50,000 payable in five equal annual instalments with the first instalment falling due in July 2016.

Summary of Significant Accoun17

Summary of Significant Accounting Policies: Basis of Presentation Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Basis of Presentation Policy	Basis of Presentation These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Summary of Significant Accoun18

Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Principles of Consolidation	Principles of Consolidation These financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions are eliminated upon consolidation.

Summary of Significant Accoun19

Summary of Significant Accounting Policies: Use of Estimates Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Use of Estimates Policy	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.

Summary of Significant Accoun20

Summary of Significant Accounting Policies: Income Taxes Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Income Taxes Policy	Income Taxes The Company complies with the FASB ASC No. 740 - Income Taxes which requires an asset and liability approach to financial accounting and reporting for income taxes. For any uncertain tax positions, the Company recognizes the impact of a tax position only if it is more likely than not of being sustained upon examination, based on the technical merits of the position. Given the lack of certainty over the Company’s ability to make profits in future the Company has not recorded any deferred tax asset in the accounts.

Summary of Significant Accoun21

Summary of Significant Accounting Policies: Cash and Cash Equivalents Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Cash and Cash Equivalents Policy	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are carried at cost, which approximates fair value. The Company places its cash and cash equivalents on deposit with a financial institution in the United States. The Federal Deposit Insurance Corporation (FDIC) covers $250,000 for substantially all depository accounts in the United States. The Company from time to time may have amounts on deposit in excess of the insured limits.

Summary of Significant Accoun22

Summary of Significant Accounting Policies: Fair Value of Financial Instruments Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Fair Value of Financial Instruments Policy	Fair Value of Financial Instruments The Company's financial instruments consist of cash, accounts payable, and a loan payable to a related party. The carrying amounts of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing rates unless otherwise disclosed in these financial statements.

Summary of Significant Accoun23

Summary of Significant Accounting Policies: Share Subscriptions Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Share Subscriptions Policy	Share Subscriptions Under the terms of a subscription agreement the Company has received funds pursuant to an issuance of stock. The stock is only issuable to the investors once the full subscription proceeds are received, which will not occur until fiscal year 2017. While the shares are un-issued it is the policy of the company to account for the received capital as Share Subscriptions.

Summary of Significant Accoun24

Summary of Significant Accounting Policies: Earnings Per Share Policy (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Earnings Per Share Policy	Earnings per Share The Company calculates earnings per share in accordance with Financial Accounting Standards Board (FASB) ASC No. 260 - EPS, which requires that basic net income per common share be computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. The Company has no share option scheme and as a result no dilutive elements were considered for the purposes of calculating earnings per share.

Summary of Significant Accoun25

Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Mar. 31, 2016
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements Fiscal 2017 Accounting Pronouncement Adoptions Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU No. 2014-15”) that will require management to evaluate whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the financial statements are issued on both an interim and annual basis. Management will be required to provide certain footnote disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. ASU No. 2014-15 becomes effective for us in the first quarter of fiscal 2017. The Company is currently evaluating the impact of ASU 2014-15 on its financial statements. Fiscal 2019 Accounting Pronouncement Adoptions Leases In February 2016, the FASB issued ASU 2016-02, Leases

Income Taxes Disclosure_ Schedu

Income Taxes Disclosure: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Mar. 31, 2016
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	March 31, March 31, 2016 2015 Federal tax at statutory rate: 34.0% 34.0% State taxes (net of Federal benefit) 5.8% 5.8% Permanent difference -0.1% 0.0% Change in Valuation Allowance -39.7% -39.8% Provision for Income Taxes 0.0% 0.0%

Income Taxes Disclosure_ Sche27

Income Taxes Disclosure: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Mar. 31, 2016
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	March 31, March 31, 2016 2015 Net Operating Loss Carryforwards 305,000 66,000 Accrued Bonus 60,000 -- Valuation Allowance (365,000) (66,000) Net Deferred Tax Assets -- --

Liquidity and Going Concern D28

Liquidity and Going Concern Disclosure (Details)	Mar. 31, 2016USD ($)
Details
working capital deficit	$ 369,784

Material Agreements Disclosure

Material Agreements Disclosure (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Details
Gain on extinguishment of debt	$ 107,884
Payments made on Collaboration Agreement	$ 32,000

Related Party Transactions Di30

Related Party Transactions Disclosure (Details) - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Due to officers	$ 6,420	$ 3,706
Accounts payable and accrued expenses	225,498	214
Gergely Toth
Due to officers	2,700	$ 3,700
Toth and Associates LTD
Monthly salary	12,000
Fixed bonus, to be paid if certain conditions are met	$ 50,000
Common stock compensation	on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital
Related party consulting fees incurred	$ 200,000
Accounts payable and accrued expenses	62,000
Capro LTD
Monthly salary	10,000
Fixed bonus, to be paid if certain conditions are met	$ 50,000
Common stock compensation	on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital
Related party consulting fees incurred	$ 170,000
Accounts payable and accrued expenses	60,000
Eden Professional LTD
Monthly salary	6,000
Fixed bonus, to be paid if certain conditions are met	$ 50,000
Common stock compensation	on the issuance of new stock for the purposes of a capital raise of an amount over $5.0 million, common stock equal to 1% of the Company’s post-investment issued share capital
Related party consulting fees incurred	$ 130,000
Accounts payable and accrued expenses	$ 56,000

Notes Payable Related Parties31

Notes Payable Related Parties Disclosure (Details)	Mar. 31, 2016USD ($)
Details
Notes payable related party	$ 16,562

Capital Stock Disclosure (Detai

Capital Stock Disclosure (Details) - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Common stock authorized for issuance	250,000,000	250,000,000
Common stock par value	$ 0.001	$ 0.001
October 31, 2015
Stock subscriptions	$ 500,000
August 18, 2015
Stock subscriptions	100,000
February 26, 2016
Stock subscriptions	$ (100,000)
Common stock issued	675,676

Commitments and Contingencies33

Commitments and Contingencies Disclosure (Details)	12 Months Ended
	Mar. 31, 2016USD ($)
Office property in Sunnyvale, CA
Monthly payments required on Property Leases	$ 1,200
Laboratory in Budapest, Hungary
Monthly payments required on Property Leases	$ 2,700

Income Taxes Disclosure_ Sche34

Income Taxes Disclosure: Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Details
Federal tax at statutory rate	34.00%	34.00%
State taxes (net of Federal benefit)	5.80%	5.80%
Permanent difference	(0.10%)	0.00%
Change in Valuation Allowance	(39.70%)	(39.80%)

Income Taxes Disclosure_ Sche35

Income Taxes Disclosure: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Details
Net operating loss carried forward	$ 305,000	$ 66,000
Accrued Bonus	60,000
Valuation Allowance	$ (365,000)	$ (66,000)

Income Taxes Disclosure (Detail

Income Taxes Disclosure (Details)	Mar. 31, 2016USD ($)
Details
Net tax loss carried forward	$ 764,000